Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52-week, open-label, parallel-group trial

Journal of Diabetes Investigation

Volumn 7, Issue 1, 2016, Pages 76-84

  Kaku, Kohei ^a   Kiyosue, Arihiro ^b   Ono, Yuri ^c   Shiraiwa, Toshihiko ^d   Kaneko, Shizuka ^e   Nishijima, Keiji ^f   Bosch Traberg, Heidrun ^g   Seino, Yutaka ^h  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b Tokyo Eki Center Building Clinic   (Japan)

^c Yuri Ono Clinic   (Japan)

^d Shiraiwa Medical Clinic   (Japan)

^e TAKATSUKI RED CROSS HOSPITAL   (Japan)

^f Novo Nordisk Pharma Ltd   (Japan)

^g NOVO NORDISK A S   (Denmark)

^h KANSAI ELECTRIC POWER CO   (Japan)

Author keywords

Liraglutide; Oral antidiabetic drug; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; GLINIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; LIRAGLUTIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; BACKACHE; CATARACT; CONSTIPATION; CONTROLLED STUDY; DENTAL CARIES; DIABETIC RETINOPATHY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INFLUENZA; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; JAPAN; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; LIRAGLUTIDE; MALE; METFORMIN; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84961295369     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12367     Document Type: Article

References (32)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
2. Japan Diabetes Society. Treatment Guide for Diabetes: 2012-2013. Available at: http://www.jds.or.jp/common/fckeditor/editor/filemanager/connectors/php/transfer.php?file=/uid000025_54726561746D656E745F47756964655F666F725F44696162657465735F323031322D323031332E706466. Accessed March 2014.
3. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-1439.
4. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000; 43: 1664-1669.
5. Agerso H, Jensen LB, Elbrond B, et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002; 45: 195-202.
6. Marre M, Shaw J, Brändle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268-278.
7. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32: 84-90.
8. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-481.
9. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009; 32: 1224-1230.
10. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52: 2046-2055.
11. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47.
12. Nauck M, Frid A, Hermansen K, et al. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes Metab 2013; 15: 204-212.
13. Garber A, Henry RR, Ratner R, et al. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13: 348-356.
14. Buse JB, Sesti G, Schmidt WE, et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010; 33: 1300-1303.
15. Kaku K, Rasmussen MF, Clauson P, et al. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 341-347.
16. Kaku K, Rasmussen MF, Nishida T, et al. Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes. J Diabetes Investig 2011; 2: 441-447.
17. Seino Y, Rasmussen MF, Nishida T, et al. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin 2010; 26: 1013-1022.
18. Seino Y, Rasmussen MF, Nishida T, et al. Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: results of a 52-week, randomized, multicenter trial. J Diabetes Investig 2011; 2: 280-286.
19. Japanese Ministry of Health, Labor and Welfare. Guideline for Clinical Evaluation of Oral Hypoglycemic Agents, 9 July 2010. Available at: http://www.pmda.go.jp/kijunsakusei/file/guideline/new_drug/keikou-kettokoukayaku_en.pdf. Accessed May 2014.
20. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
21. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Last amended by the 59th WMA General Assembly, Seoul 2008.
22. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6 (R1), Step 4, dated 10 June 1996.
23. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013; 36: 1384-1395.
24. Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin in patients with type 2 diabetes inadequately controlled on metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010; 375: 1447-1456.
25. Davies MJ, Kela R, Khunti K. Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Diabetes Obes Metab 2011; 13: 207-220.
26. Steinberg W, DeVries JH, Wadden TA, et al. Longitudinal monitoring of lipase and amylase in adults with type 2 diabetes and obesity: evidence from two phase 3 randomized clinical trials with the once-daily GLP-1 analog liraglutide. Gastroenterology 2012; 142: S850-S851.
27. Nicolucci A, Rossi MC. Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes. Acta Biomed 2008; 79: 184-191.
28. Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002; 143: 4397-4408.
29. Rolin B, Larsen MO, Gotfredsen CF, et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002; 283: E745-E752.
30. Hui H, Nourparvar A, Zhao X, et al. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 2003; 144: 1444-1455.
31. Li Y, Hansotia T, Yusta B, et al. Glucagon-like peptide-1 receptor signaling modulates β-cell apoptosis. J Biol Chem 2003; 278: 471-478.
32. Bregenholt S, Møldrup A, Blume N, et al. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro. Biochem Biophys Res Commun 2005; 330: 577-584.